Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new product, AGN-151586, to see if it is safe and effective in treating moderate to severe glabellar lines (frown lines). The study is double-blind, meaning that neither the participant nor the researcher will know who is receiving AGN-151586 or Placebo. The study will last for 12 weeks, and participants will be given 5 intramuscular injections on the first day. Participants may be eligible for open-label treatment during the study if they meet certain criteria.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 198 Patients • NCT04096326Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many test subjects are included in this clinical trial?
"600 participants that match the study's prerequisites are necessary to complete the trial. The sponsor, Allergan, will be running the show from different sites including KGL Skin Study Center, LLC /ID# 233549 in Newtown Square, Pennsylvania and Total Skin and Beauty Derm Ctr /ID# 232378 in Birmingham, Alabama."
In how many different hospitals is this medical study being run today?
"Presently, this clinical trial is recruiting patients from 22 different sites. The locations are situated in Newtown Square, Birmingham and Encino as well as other cities. To limit travel requirements, please select the location nearest you."
Are new participants being welcomed into this clinical trial?
"Yes, this clinical trial is looking for participants and has been since it was originally posted on March 4th, 2022. According to the website, the last update to the trials information was on October 24th, 2022."
What are the potential risks associated with AGN-151586?
"AGN-151586 has received a 3 for safety. This is due to the fact that it is a Phase 3 trial, which suggests that not only does this drug have some evidence of efficacy, but there are also multiple rounds of data supporting its safety."
What are the goals researchers hope to achieve with this clinical trial?
"The primary outcome of this study is the number of participants with adverse events, which will be measured over a period of 7 days. Secondary outcomes include the percentage of participants who are mostly or very satisfied with the treatment according to the Facial Line Satisfaction Questionnaire (FLSQ), the percentage of participants who show a 2-grade improvement in facial wrinkles from baseline, and the percentage of participants who are mostly or very satisfied with the natural look of their skin after treatment."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger